Home > Boards > US Listed > Biotechs > Minerva Neurosciences, Inc. (NERV)

READ I’m BULLISH NOW - they now know dosage....they

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Toddrobertking Member Profile
 
Followed By 2
Posts 440
Boards Moderated 0
Alias Born 08/26/18
160x600 placeholder
Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020 GlobeNewswire Inc. - 10/26/2020 8:30:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/14/2020 5:22:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/14/2020 5:21:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/14/2020 5:19:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/14/2020 5:19:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/14/2020 5:17:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/14/2020 4:59:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2020 5:14:30 PM
Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire Inc. - 9/9/2020 8:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/8/2020 7:14:11 AM
Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference GlobeNewswire Inc. - 9/2/2020 8:30:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:33:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:32:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:31:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:31:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:29:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:29:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:27:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:26:33 PM
Minerva Neurosciences to Present at JMP Securities CNS Forum GlobeNewswire Inc. - 8/13/2020 8:00:10 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/10/2020 6:10:55 AM
Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates GlobeNewswire Inc. - 8/3/2020 7:30:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/3/2020 7:01:32 AM
Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020 GlobeNewswire Inc. - 7/27/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2020 5:29:29 PM
Toddrobertking   Tuesday, 06/02/20 01:07:42 PM
Re: None
Post # of 157 
READ

I’m BULLISH NOW - they now know dosage....they will tweak and work with FDA....this price is a gift

64 mg dose was statistically significantly different from placebo as measured by change in PSP at all other assessment timepoints (Week 4, nominal p ≤0.005, ES=0.3; Week 8: nominal p ≤0.018, ES=0.3).

“The substantial improvements in the PSP scale with the 64 mg dose are tremendously encouraging. These study results represent a very important outcome in a study of a potential treatment of negative symptoms, one of the most important drivers of everyday disability and a critical unmet medical need for patients with schizophrenia. The consistency in treatment effects, in terms of overall negative symptoms and of the most important subtype, reduced emotional experience, between the previous Phase 2b study and the current one is encouraging. The increased placebo effect from the first to second study seems to be the only reason that the study did not meet its primary endpoint.”

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences